Qualia Pharma and Bionature signed a collaboration agreement on the clinical development of a novel class of molecules (called Microneurotrophins) for treating Alzheimer’s disease. Bionature E.A. Ltd, a biotechnology company, spin off of the University of Crete, and Qualia Pharma S.A., a Greek pharmaceutical company specialising in Central Nervous System are joining forces to develop a new pluripotent treatment, with neuroprotective and neuroregenerative activity.